The global liver fibrosis treatment market, valued at USD 16.43 billion in 2022, is projected to reach an astounding USD 46.65 billion by 2033, growing at an impressive CAGR of 11% during the forecast period from 2023 to 2033, according to a new report by Future Market Insights.
Liver fibrosis, a key indicator of numerous liver disorders, is drawing increased attention from healthcare professionals focused on slowing or preventing liver scarring. While not a disease in itself, liver fibrosis is closely linked to conditions like autoimmune hepatitis, chronic alcoholism, and metabolic storage disorders such as Galactosemia, Wilson disease, and iron-overload syndromes. Additionally, viral and parasitic infections that impair hepatic blood flow further complicate the condition’s management.
Non-alcoholic Steatohepatitis (NASH) as a Growth Catalyst:
One of the major factors driving the liver fibrosis treatment market is the surge in Non-alcoholic Steatohepatitis (NASH) cases. With increasing awareness and investment in NASH treatment, the market is witnessing a significant boost. Private research organizations are pouring resources into developing new therapies targeting liver fibrosis and related fatty liver diseases. This trend is expected to fuel market growth exponentially over the coming decade.
Milestone in Pediatric Hepatitis C Treatment:
A critical breakthrough in liver disease treatment came in April 2019 when the U.S. Food and Drug Administration (FDA) approved AbbVie’s Mavyret, the first confirmed treatment for pediatric Hepatitis C patients across all genotypes. This landmark approval highlights the growing emphasis on innovative treatments for liver fibrosis and associated liver conditions.
Challenges in the Market:
Despite promising growth, the liver fibrosis treatment market faces challenges, particularly the high costs associated with treatment. According to the Centers for Disease Analysis, the U.S. alone spends roughly USD 5 billion annually on liver disease-related healthcare costs, including hospitalizations, screenings, transplants, and chemotherapy. These financial burdens could slow market growth if left unaddressed.
Prevalence of NAFLD and NASH:
Non-alcoholic Fatty Liver Disease (NAFLD), identified by the National Institute of Health as the most common liver disease worldwide, accounts for 25% of global cases. In the U.S., a variant of NAFLD, Non-alcoholic Steatohepatitis (NASH), affects about 5% of the population, underscoring the critical need for advanced liver fibrosis treatments.
Future Outlook:
According to the latest report from Future Market Insights, the liver fibrosis treatment market is on a robust growth trajectory. The report provides an in-depth analysis of market trends and drivers, leveraging the expertise of experienced analysts who employed comprehensive research methodologies.
“With growing incidences of liver disorders, the global liver fibrosis treatment market is expected to grow on an unprecedented note going forward,” says an analyst from Future Market Insights.
Key Takeaways from Liver Fibrosis Treatment Market
- North America holds the largest market share with a plethora of drug molecules available for improving treatment process with technological development in this region’s rehabilitation. Also, the key participants are into increasingly spending on healthcare. Also, the fact that NAFLD (Non-Alcoholic Fatty Liver Disorder) ends up affecting close to 20% of Canadians can’t be let off.
- The Asia-Pacific is expected to grow at the quickest rate in the liver fibrosis treatment market on the back of advancements in the medical infrastructure in countries like India, China, and the other South-East Asian economies. Also, there is a growing pool of people contracting Hepatitis C herein.
Stay Ahead with Liver Fibrosis Treatment: Delve into Our Full Report for Extensive Trends and Insights!
Competitive Treatment
- Aligos Therapeutics Inc., in December 2020, did enter into collaboration with Merck & Co. Inc. for creating a therapy regarding liver fibrosis treatment.
- Gilead Sciences Inc., in March 2019, did launch HepConnect Program for reducing Hepatitis C Infections in ‘Greater Appalachia’.
- Beijing Continent Pharmaceutical Co., Ltd., in January 2022, upgraded clinical trial regarding Hydronidone capsules to phase 3. It had finished with an effective Phase II clinical trial in December 2021. The Phase III trial is expected to be completed in June 2024.
- HepC, under its vector scheme, has its non-pathogenic double-stranded RNA virus behave as one of the expert inducers of anti-viral gene reactions. It is into development of HC001 for curing chronic viral hepatitis caused due to HCV and HBV infections.
What does the Report say?
- The research study is based on treatment type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE inhibitors, hepatotropic drug, and likewise), condition (chronic liver diseases, Hepatitis C, and non-alcoholic steatohepatitis), and end-user (hospitals, specialty clinics, and likewise).
- With fatalities out of cirrhosis of liver on the rise, the global liver fibrosis treatment market is bound to grow on an astonishing note going forward.
Key Companies Profiled:
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Johnson and Johnson
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- Pfizer Inc.
- FibroGen, Inc.
- Inventiva Pharma
- Pharmaxis Limited
Key Segments Profiled in the Liver Fibrosis Treatment Industry Survey
By Treatment Type:
- Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
- ACE Inhibitors
- Hepatotropic Drug
- Others
By Condition:
- Chronic Liver Diseases
- Hepatitis C
- Nonalcoholic Steatohepatitis
By End User:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube